Patents by Inventor Hans Rink
Hans Rink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7541018Abstract: In one embodiment, a method for treating a cancerous disease is provided which includes characterizing a disease by an overexpression of one or more somatostatin receptors, and exposing the one or more somatostatin receptors to a pharmaceutical composition comprising a somatostatin analogue which binds to the one or more somatostatin receptors.Type: GrantFiled: March 8, 2007Date of Patent: June 2, 2009Assignee: University of BernInventors: Helmut Robert Maecke, Jean Claude Reubi, Hans Rink, Klaus-Peter Eisenwiener
-
Publication number: 20070154392Abstract: In one embodiment, a method for treating a cancerous disease is provided which includes characterizing a disease by an overexpression of one or more somatostatin receptors, and exposing the one or more somatostatin receptors to a pharmaceutical composition comprising a somatostatin analogue which binds to the one or more somatostatin receptors.Type: ApplicationFiled: March 8, 2007Publication date: July 5, 2007Inventors: Helmut Maecke, Jean Reubi, Hans Rink, Klaus-Peter Eisenwiener
-
Patent number: 7192570Abstract: In one embodiment, a composition of somatostatin analogues having the general formula: is provided wherein Z may be absent or present and when present is selected from DOTA- and DTPA-based chelators, NOTA-based chelators, carbonyl compounds, hydrazino nicotinamide, N4-chelators, desferrioxamine, NxSy-chelators, optionally complexed or labeled with a radioisotope, tyrosine for halogenation, a fluorescent dye, or biotin. The composition further provides that L may or may not be present and when present is a linker molecule, X1 is glutamic acid or a symmetric or asymmetric diamino acid containing 3 or 4 consecutive C atoms, X2 is a positively charged natural or unnatural amino acid, an arginine mimic, citrulline, or a neutral amino acid, X3 is phenylalanine, Ala-[3-(2-thienyl)], ?-naphthylalanine, or ?-naphthylalanine, X4 is an aromatic amino acid, X5 is threonine or serine, and X6 is phenylalanine, Ala-[3-(2-thienyl)], ?-naphthylalanine, or ?-naphthylalanine.Type: GrantFiled: August 7, 2002Date of Patent: March 20, 2007Assignee: University of BernInventors: Helmut Robert Maecke, Jean Claude Reubi, Hans Rink, Klaus-Peter Eisenwiener
-
Publication number: 20040242842Abstract: The present invention relates to novel somatostatin analogues of the general formula (I) wherein Z may be absent or present and when present is selected from the group consisting of DOTA- and DTPA-based chelators, NOTA-based chelators, cabonyl compounds, hydrazino nicotinamide (hynic), N4-chelators, desferrioxamin, NxSy-chelators, all optionally complexed or labeled with a radioisotope, Tyrosine (Tyr) for halogenation, a fluorescent dye or biotin; L may or may not be present and is a linker molecule; X1 is a symmetric or asyrnmetric diamino acid, containing 3 or 4 consecutive C atoms with a linker to the chelating agent, for example D/L-diamino butyric acid (D/L-Dab) for a more basic character or D/L-Glu for coupling to primary and secondary amino groups; X2 is a positively charged natural or unnatural amino acid or arginine mimic or citrulline, or a neutral amino acid like Asn; X3 is phenylalanine (Phe), Ala-[3-(2-thienyl)] or &agr;-,&bgr;-naphthylalanine; X4 is an aromatic amino acid, optionally hType: ApplicationFiled: July 21, 2004Publication date: December 2, 2004Inventors: Helmut Robert Maecke, Jean Claude Reubi, Hans Rink, Klaus-Peter Eisenwiener
-
Publication number: 20020142414Abstract: The invention relates to DNA sequences which code an eglin, expression plasmids containing such DNA sequences, hosts transformed with such expression plasmids, novel eglin compounds produced from such transformed hosts, monoclonal antibodies against eglins, hybridoma cells which produce such antibodies, and test kits for immunoassays containing such antibodies, and furthermore the processes for their preparation and a process for the preparation of eglins with the aid of the transformed hosts. The eglins which can be prepared according to the invention have useful pharmacological properties.Type: ApplicationFiled: January 22, 2001Publication date: October 3, 2002Applicant: UCP Gen-Pharma AGInventors: Hans Rink, Manfred Liersch, Peter Sieber, Werner Rittel, Francois Meyer, Ursula Seemuller, Hans Fritz, Walter Marki, Sefik Alkan
-
Patent number: 6342373Abstract: The invention relates to DNA sequences which code an eglin, expression plasmids containing such DNA sequences, hosts transformed with such expression plasmids, novel eglin compounds produced from such transformed hosts, monoclonal antibodies against eglins, hybridoma cells which produce such antibodies, and test kits for immunoassays containing such antibodies, and furthermore the processes for their preparation and a process for the preparation of eglins with the aid of the transformed hosts. The eglins which can be prepared according to the invention have useful pharmacological properties.Type: GrantFiled: May 24, 1991Date of Patent: January 29, 2002Assignee: UCP GEN-Pharma AGInventors: Hans Rink, Manfred Liersch, Peter Sieber, Werner Rittel, Francois Meyer, Ursula Seemüller, Hans Fritz, Walter Märki, Sefik Alkan
-
Patent number: 5728549Abstract: The invention relates to DNA sequences that code for the amino acid sequence of the thrombin inhibitor hirudin, hybrid vectors containing such DNA sequences, host cells transformed with such hybrid vectors, novel polypeptides with thrombin-inhibiting activity produced from such transformed host cells, processes for the manufacture of these DNA sequences, hybrid vectors and transformed host cells, and processes for the manufacture of these thrombin-inhibitors using the transformed host cells. The hirudin compounds that can be produced according to the invention have valuable pharmacological properties.Type: GrantFiled: March 3, 1995Date of Patent: March 17, 1998Assignee: Novartis CorporationInventors: Manfred Liersch, Hans Rink, Walter Marki, Markus Gerhard Grutter, Bernd Meyhack
-
Patent number: 5686564Abstract: Novel compounds of the formula I ##STR1## in which R.sup.1 and R.sup.2 are hydrogen, C.sub.1 -C.sub.4 alkyl or are linked to form C.sub.3 -C.sub.7 cycloalkyl and R.sup.3, R.sup.4 and R.sup.5 are the same or different and are hydrogen, C.sub.1 -C.sub.4 alkyl, hydroxy, OR.sup.6, SR.sup.6, halogen, NR.sup.7 R.sup.8, NO.sub.2, CN, CONR.sup.7 R.sup.8 or CO.sub.2 R.sup.9 wherein R.sup.6 is C.sub.1 -C.sub.4 alkyl or C.sub.7 -C.sub.10 aralkyl and R.sup.7, R.sup.8 and R.sup.9 are the same or different and are hydrogen, C.sub.1 -C.sub.4 alkyl or C.sub.7 -C.sub.10 aralkyl or R.sup.7 and R.sup.8 together with the nitrogen atom to which they are bound form 5 or 6 membered azacycloalkyl or oxazacycloalkyl; Arg is arginine ?NH--CH(CH.sub.2 CH.sub.2 CH.sub.2 NH--C(.dbd.NH)--NH.sub.2)--CO!; X is methine CH or nitrogen; n is an integer from 0 to 7; L is a peptide linker, and H is the carboxy terminal end of hirudin, and salts thereof, are provided.Type: GrantFiled: October 20, 1994Date of Patent: November 11, 1997Assignee: Novartis CorporationInventors: Derek Edward Brundish, Hans Rink, Markus Grutter, John Peter Priestle, Albert Schmitz
-
Patent number: 5422249Abstract: The invention relates to DNA sequences that code for the amino acid sequence of the thrombin inhibitor hirudin, hybrid vectors containing such DNA sequences, host cells transformed with such hybrid vectors, novel polypeptides with thrombin-inhibiting activity produced from such transformed host cells, processes for the manufacture of these DNA sequences, hybrid vectors and transformed host cells, and processes for the manufacture of these thrombin-inhibitors using the transformed host cells. The hirudin compounds that can be produced according to the invention have valuable pharmacological properties.Type: GrantFiled: September 15, 1993Date of Patent: June 6, 1995Assignees: Ciba-Geigy Corporation, UCP Gen-Pharma AGInventors: Manfred Liersch, Hans Rink, Walter Marki, Markus G. Grutter, Bernd Meyhack
-
Patent number: 5354843Abstract: Peptides of formula I ##STR1## in which R is hydrogen or acetyl and X is an amino acid sequence of formula -Ser-Leu-Asp-Ser-Pro-Arg-Ser- (Ia) or of formula -Arg-Ile-Ile-Ala-Gln- (Ib), and salts of such compounds, can be used for the treatment of diseases involving bone degeneration.Type: GrantFiled: August 23, 1989Date of Patent: October 11, 1994Assignee: Ciba-Geigy CorporationInventors: Hans Rink, Klaus Muller
-
Patent number: 5093530Abstract: A synthetic resin based on a polystyrene that can be used as a support for solid phase peptide synthesis and that has been cross-linked with from 0 to 5 mol % of divinyl benzene, characterized in that it has been substituted at benzene rings of its skeletal structure by groups of the formula ##STR1## in which X represents --O-- or --NH-- and R represents C.sub.1 -C.sub.4 -alkyl, as a support renders possible the solid phase synthesis of peptides and peptide amides that are, if desired, protected at the N-terminal and/or at other functional groups. The resin is manufactured by reaction of a customary chloromethylated polystyrene resin with an alkali metal salt of the corresponding 4-hydroxybenzophenone and subsequent reduction of the carbonyl group and, optionally, amination.Type: GrantFiled: June 20, 1991Date of Patent: March 3, 1992Assignee: Ciba-Geigy CorporationInventor: Hans Rink
-
Patent number: 5004781Abstract: A synthetic resin based on a polystyrene that can be used as a support for solid phase peptide synthesis and that has been cross-linked with from 0 to 5 mol % of divinyl benzene, characterized in that it has been substituted at benzene rings of its skeletal structure by groups of the formula ##STR1## in which X represents --O-- or --NH-- and R represents C.sub.1 -C.sub.4 -alkyl, as a support renders possible the solid phase synthesis of peptides and peptide amides that are, if desired, protected at the N-terminal and/or at other functional groups. The resin is manufactured by reaction of a customary chloromethylated polystyrene resin with an alkali metal salt of the corresponding 4-hydroxybenzophenone and subsequent reduction of the carbonyl group and, optionally, amination.Type: GrantFiled: May 17, 1989Date of Patent: April 2, 1991Assignee: Ciba-Geigy CorporationInventor: Hans Rink
-
Patent number: 4859736Abstract: A synthetic resin based on a polystyrene that can be used as a support for solid phase peptide synthesis and that has been cross-linked with from 0 to 5 mol % of divinyl benzene, characterized in that it has been substituted at benzene rings of its skeletal structure by groups of the formula ##STR1## in which X represents --O-- or --NH-- and R represents C.sub.1 -C.sub.4 -alkyl, as a support renders possible the solid phase synthesis of peptides and peptide amides that are, if desired, protected at the N-terminal and/or at other functional groups. The resin is manufactured by reaction of a customary chloromethylated polystyrene resin with an alkali metal salt of the corresponding 4-hydroxybenzophenone and subsequent reduction of the carbonyl group and, optionally, amination.Type: GrantFiled: March 21, 1988Date of Patent: August 22, 1989Assignee: Ciba-Geigy CorporationInventor: Hans Rink
-
Patent number: 4720483Abstract: Described are peptides that have, as partial sequence of a larger peptide, or exclusively, the amino acid sequence of the formula I ##STR1## in which the cysteine residues can form intra- or inter-molecular disulphide bridges, and derivatives thereof having an amidated terminal carboxy group and/or an acylated terminal amino group, and their salts, DNA sequences that code for the mentioned peptides, micro-organisms that contain these DNA sequences, processes for the manufacture thereof, pharmaceutical preparations that contain the mentioned peptides in the form of their amides, and the use of these peptide-amides for the treatment of coronary circulation disorders and bone metabolism disorders.Type: GrantFiled: January 15, 1986Date of Patent: January 19, 1988Assignee: Ciba-Geigy CorporationInventors: Hendrik S. Jansz, Cornelis J. M. Lips, Paul H. Steenbergh, Hans Rink, Peter Sieber
-
Patent number: 4369179Abstract: Acylpeptides derived from somatostatin or from a derivative thereof having analogous action, in which the amino acids sequence is modified by omitting individual amino acids and/or by exchanging them for other amino acids, and in which the .epsilon.-amino group of the lysine residue in the 9-position, and optionally also the .epsilon.-amino group of the lysine residue in the 4-position and/or the N-terminal .alpha.-amino group carries the acyl radical of an optionally substituted alkanecarboxylic acid, and salts and complexes thereof can be used as antidiabetics and/or for combating gastrointestinal bleeding. They are manufactured by conventional methods of peptide chemistry.Type: GrantFiled: December 5, 1980Date of Patent: January 18, 1983Assignee: Ciba-Geigy CorporationInventors: Hans Rink, Peter Sieber, Bruno Kamber
-
Patent number: 4358439Abstract: Cyclic peptides of the formula ##STR1## in which trp represents L-Trp, D-Trp, or an analogous radical which carries a halogen atom in the indole nucleus, Ac.sub.A represents hydrogen, or an acyl radical Ac of a carboxylic acid present at the .epsilon.-amino group, A represents L-Phe, D-Phe, L-Phg or D-Phg, or a corresponding radical having a substituted or saturated phenyl ring, and B represents the residue of a .gamma.- or .delta.-amino-lower alkanecarboxylic acid which may carry an optionally substituted cyclic hydrocarbyl radical Ar, and also pharmacologically tolerable salts and therapeutically acceptable complexes thereof can be used as an antidiabetic in an analogous manner to somatostatin. They can be obtained by conventional processes of peptide chemistry, especially by cyclisation of corresponding linear peptides.Type: GrantFiled: December 15, 1980Date of Patent: November 9, 1982Assignee: Ciba-Geigy CorporationInventors: Peter Sieber, Bruno Kamber, Hans Rink
-
Patent number: 4328214Abstract: The somatostatin-analogous cyclic octapeptides according to the invention of the general formula ##STR1## in which trp represents L-Trp or D-Trp, in which the benzene ring may be substituted by a halogen atom, andGaba(Ar) represents the residue of a .gamma.-aminobutyric acid substituted by a cyclic hydrocarbyl radical,and their acid addition salts and complexes are distinguished by a strong inhibition of the insulin and glucagon secretion of the pancreas and are therefore therapeutically acceptable, preferably in the form of pharmaceutical preparations, in similar indications to those of somatostatin, especially as anti-diabetics. The compounds are manufactured by conventional processes of peptide synthesis, especially by liberation from corresponding protected intermediates after intramolecular cyclization of a corresponding linear octapeptide.Type: GrantFiled: June 25, 1980Date of Patent: May 4, 1982Assignee: Ciba-Geigy CorporationInventors: Hans Rink, Peter Sieber, Bruno Kamber
-
Patent number: 4316890Abstract: The somatostatin-analogous peptides according to the invention of the general formula ##STR1## in which Bmp represents the desaminocysteine radicalX represents Asn or His,trp represents D-Trp that may be substituted in the benzene ring by a halogen atom, andY represents the radical of a secondary .alpha.-amino acid having a maximum of 8 carbon atomsand the corresponding peptide amides and also acid addition salts and complexes thereof are distinguished by strong insulin-antagonistic and glucagon-antagonistic effects and are therefore therapeutically acceptable, preferably in the form of pharmaceutical preparations, in similar indications to those of somatostatin, especially also as antidiabetics. The compounds are manufactured by conventional processes of peptide synthesis, especially by liberation from corresponding protected intermediates and by the formation of the cystine disulphide bridge by means of oxidation.Type: GrantFiled: March 10, 1980Date of Patent: February 23, 1982Assignee: Ciba-Geigy CorporationInventors: Bruno Kamber, Hans Rink, Peter Sieber
-
Patent number: 4238481Abstract: Sulphur-free cyclopeptides with somatostatin-analogous aminoacid partial sequences, of the formula ##STR1## in which R is Asn, Ala or de-R, trp is D-Trp or L-Trp, which can be substituted in the benzene ring by halogen atoms or nitro groups, W is a free or etherified hydroxyl group or halogen atom present as a substituent on the benzene ring of the L-phenylalanine radical, or is hydrogen, X is the radical of an .omega.-amino-lower alkane-(mono or di)-carboxylic acid or de-X and Y is the radical of an .omega.-amino-lower alkane-(mono or di)-carboxylic acid or de-Y, and also acid addition salts and complexes thereof have biological properties similar to those of somatostatin and can be used, especially in the form of pharmaceutical preparations, for the treatment of excessive secretion of somatotropin, insulin and/or glucagon. The compounds according to the invention are obtained by cyclising a corresponding linear peptide compound in which the .epsilon.Type: GrantFiled: September 15, 1978Date of Patent: December 9, 1980Assignee: Ciba-Geigy CorporationInventors: Hans Rink, Bruno Kamber, Peter Sieber